Literature DB >> 25274101

Non-alcoholic fatty liver disease: need for a balanced nutritional source.

Jayagopalan Veena1, Anjaneyulu Muragundla1, Srinivas Sidgiddi2, Swaminathan Subramaniam2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are an increasingly common chronic liver disease closely associated with diabetes and obesity that have reached epidemic proportions. Reports on the prevalence of NAFLD have suggested that 27-34% of the general population in the USA and 40-90% of the obese population worldwide have this disease. Increasing urbanisation rate and associated inappropriate lifestyle changes are not only the risk factors of diabetes, but also unmask genetic predisposition in various populations for the metabolic syndrome and its manifestations including NAFLD and NASH. Lifestyle modifications and balanced nutrition are among the foremost management strategies along with ursodeoxycholic acid, metformin, vitamin E and pentoxifylline. Although weight reduction associated with current therapeutic strategies has shown some promise, maintaining it in the long run is largely unsuccessful. With the safety of pharmacotherapy still being uncertain and can be started only after confirmation, other reasonable interventions such as nutrition hold promise in preventing disease progression. The role of dietary components including branched-chain amino acids, methionine, choline and folic acid is currently being evaluated in various clinical trials. Nutritional approaches sought to overcome the limitations of pharmacotherapy also include evaluating the effects of natural ingredients, such as silymarin and spirulina, on liver disease. Understanding the specific interaction between nutrients and dietary needs in NAFLD and maintaining this balance through either a diet or a nutritional product thus becomes extremely important in providing a more realistic and feasible alternative to treat NAFLD. A planned complete nutritional combination addressing specific needs and helping to prevent the progression of NAFLD is the need of the hour to avert people from ending up with complications.

Entities:  

Mesh:

Year:  2014        PMID: 25274101     DOI: 10.1017/S0007114514002591

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  13 in total

Review 1.  New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.

Authors:  Natalia Pydyn; Katarzyna Miękus; Jolanta Jura; Jerzy Kotlinowski
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

Review 2.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

3.  The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus.

Authors:  Weiling Leng; Mingxia Wu; Hang Pan; Xiaotian Lei; Liu Chen; Qinan Wu; Xinshou Ouyang; Ziwen Liang
Journal:  Ann Transl Med       Date:  2019-09

4.  The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH).

Authors:  Rohini Mehta; Kianoush Jeiran; Aaron B Koenig; Munkzhul Otgonsuren; Zachary Goodman; Ancha Baranova; Zobair Younossi
Journal:  BMC Med Genet       Date:  2016-09-05       Impact factor: 2.103

5.  Identification of Metabolic risk phenotypes predisposing to Non-Alcoholic Fatty Liver Disease in a Pakistani Cohort.

Authors:  Rizwana Abdul Ghani; Muhammad Saqlain; Muhammad Mobeen Zafar; Shagufta Jabeen; Syed Muhammad Saqlan Naqvi; Ghazala Kaukab Raja
Journal:  Pak J Med Sci       Date:  2017 Jan-Feb       Impact factor: 1.088

Review 6.  Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: A review.

Authors:  Naiade Silveira Almeida; Raquel Rocha; Helma Pinchemel Cotrim; Carla Daltro
Journal:  World J Hepatol       Date:  2018-10-27

7.  Non-alcoholic fatty liver and the gut microbiota.

Authors:  Stavros Bashiardes; Hagit Shapiro; Shachar Rozin; Oren Shibolet; Eran Elinav
Journal:  Mol Metab       Date:  2016-06-14       Impact factor: 7.422

8.  Nutritional Strategies for the Individualized Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) Based on the Nutrient-Induced Insulin Output Ratio (NIOR).

Authors:  Ewa Stachowska; Karina Ryterska; Dominika Maciejewska; Marcin Banaszczak; Piotr Milkiewicz; Małgorzata Milkiewicz; Izabela Gutowska; Piotr Ossowski; Małgorzata Kaczorowska; Dominika Jamioł-Milc; Anna Sabinicz; Małgorzata Napierała; Lidia Wądołowska; Joanna Raszeja-Wyszomirska
Journal:  Int J Mol Sci       Date:  2016-07-22       Impact factor: 5.923

9.  Association between Dietary Vitamin C Intake and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Middle-Aged and Older Adults.

Authors:  Jie Wei; Guang-Hua Lei; Lei Fu; Chao Zeng; Tuo Yang; Shi-Fang Peng
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

10.  High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in guinea pigs.

Authors:  David Højland Ipsen; Pernille Tveden-Nyborg; Bidda Rolin; Günaj Rakipovski; Maria Beck; Line Winther Mortensen; Lasse Færk; Peter Mikael Helweg Heegaard; Peter Møller; Jens Lykkesfeldt
Journal:  Nutr Metab (Lond)       Date:  2016-08-09       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.